Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis has hit its primary endpoint, positioning the company to submit the BTK inhibitor for approval. But the discovery that more patients died on fenebrutinib than on the control drug has spurred further analyses by Roche.
Resonate Group, an ambitious Nigerian indigenous company with global aspirations, that aligns her vision with strategic intent to provide innovative solutions and services in Oil & Gas, Maritime, Manufacturing, Finance, Steel, Healthcare, and Supply Chain sectors of the Nigerian economy...
